Selfotel

Selfotel

SCHEMBL120234

O=C(O)[C@@H]1C[C@H](CP(=O)(O)O)CCN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
ALDH1A1 P00352 1/20 1.00
CYP1A2 P05177 1/20 1.00
THRB P10828 1/20 1.00
ALOX15 P16050 1/20 1.00
CYP2C19 P33261 1/20 1.00
GRIN2D O15399 1/20 1.00
GRIN3B O60391 1/20 1.00
GRIA1 P42261 1/20 1.00
GRIA2 P42262 1/20 1.00
GRIA3 P42263 1/20 1.00
GRIA4 P48058 1/20 1.00
GRIN1 Q05586 1/20 1.00
GRIN2A Q12879 1/20 1.00
GRIN2B Q13224 1/20 1.00
GRIN2C Q14957 1/20 1.00
GRIN3A Q8TCU5 1/20 1.00
KDM4E B2RXH2 1/20 0.61
ARG1 P05089 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Selfotel SCHEMBL13431267 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL120235 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL20553546 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL120236 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL16392882 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL9603151 0.98 MEN1 (0.97) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL9602901 0.98 MEN1 (0.97) MEN1KMT2AALDH1A1CYP1A2THRB
Selfotel SCHEMBL9603159 0.98 MEN1 (0.97) MEN1KMT2AALDH1A1CYP1A2THRB
SCHEMBL13431281 0.87 MEN1 (0.77) MEN1KMT2AALDH1A1CYP1A2THRB
SCHEMBL5058512 0.85 MEN1 (0.73) MEN1KMT2AALDH1A1CYP1A2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2752 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12589097-B2 Apilimod compositions and methods of use OrphAl Therapeutics Inc. (US) 2026-03-31 US claimed
US-12539337-B2 Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels Molokanova, Elena (US) 2026-02-03 US claimed
EP-4629989-A2 TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY Freedom Biosciences, Inc. (US) 2025-10-15 EP claimed
EP-4623932-A1 AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA National University Corporation Chiba University (JP) 2025-10-01 EP claimed
EP-3441087-B1 METHODS OF TREATING CHRONIC PAIN TEVA PHARMACEUTICALS INT GMBH (CH) 2025-02-19 EP claimed
WO-2025030033-A1 APILIMOD COMPOSITIONS AND METHODS OF USE ORPHAI THERAPEUTICS INC. (US) 2025-02-06 WO claimed
US-20240350432-A1 CENTRAL NERVOUS SYSTEM MODULATORS AS COVID-19 THERAPEUTICS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, 2024-10-24 US claimed
US-20240350433-A1 TREATMENT COMPOSITIONS AND METHODS UNIV YALE (US) 2024-10-24 US claimed
US-20240335430-A1 Combination Therapy for Treating or Preventing Depression or Other Mood Diseases UNIV YALE (US) 2024-10-10 US claimed
CN-118178676-A Bionic nanoparticle for sequential delivery of thrombolytic drug and neuroprotective drug, and preparation method and application thereof 南京中医药大学 2024-06-14 CN claimed
WO-1995031986-A1 COMBINATION PRODUCT OF DICHLOROACETIC ACID AND AN NMDA ANTAGONIST ASTRA AKTIEBOLAG (SE) 1995-11-30 WO claimed
EP-0533832-A4 TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX US COMMERCE (US) 1993-04-28 EP claimed
EP-0533832-A1 TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) 1993-03-31 EP claimed
EP-0488959-A2 New uses of competitive NMDA receptor antagonists SANDOZ LTD. (CH) 1992-06-03 EP claimed
WO-1991019493-A1 TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1991-12-26 WO claimed
EP-0432994-A2 Excitatory amino acid antagonists as anti-emetic drugs Olney, John William (US) 1991-06-19 EP claimed
EP-0203891-B1 CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES CIBA-GEIGY AG (CH) 1991-05-15 EP claimed
US-4916125-A ADMINISTERING E-2-AMINO-4-METHYL-5-PHOSPHONO-3-PENTENOIC ACID SANDOZ LTD. (CH) 1990-04-10 US claimed
US-4898854-A NERVOUS SYSTEM DISORDERS CIBA-GEIGY CORPORATION (US) 1990-02-06 US claimed
EP-0203891-A2 Certain phosphonic acids and derivatives CIBA-GEIGY AG (CH) 1986-12-03 EP claimed